Cargando…
Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, aba...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997274/ https://www.ncbi.nlm.nih.gov/pubmed/33671007 http://dx.doi.org/10.3390/vaccines9030203 |
_version_ | 1783670291612827648 |
---|---|
author | Richi, Patricia Yuste, Jose Navío, Teresa González-Hombrado, Laura Salido, Marina Thuissard-Vasallo, Israel Jiménez-Díaz, Ana Llorente, Jesús Cebrián, Laura Lojo, Leticia Steiner, Martina Cobo, Tatiana Martín, María Dolores García-Castro, Marta Castro, Patricia Muñoz-Fernández, Santiago |
author_facet | Richi, Patricia Yuste, Jose Navío, Teresa González-Hombrado, Laura Salido, Marina Thuissard-Vasallo, Israel Jiménez-Díaz, Ana Llorente, Jesús Cebrián, Laura Lojo, Leticia Steiner, Martina Cobo, Tatiana Martín, María Dolores García-Castro, Marta Castro, Patricia Muñoz-Fernández, Santiago |
author_sort | Richi, Patricia |
collection | PubMed |
description | Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol. |
format | Online Article Text |
id | pubmed-7997274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79972742021-03-27 Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases Richi, Patricia Yuste, Jose Navío, Teresa González-Hombrado, Laura Salido, Marina Thuissard-Vasallo, Israel Jiménez-Díaz, Ana Llorente, Jesús Cebrián, Laura Lojo, Leticia Steiner, Martina Cobo, Tatiana Martín, María Dolores García-Castro, Marta Castro, Patricia Muñoz-Fernández, Santiago Vaccines (Basel) Article Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol. MDPI 2021-02-28 /pmc/articles/PMC7997274/ /pubmed/33671007 http://dx.doi.org/10.3390/vaccines9030203 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Richi, Patricia Yuste, Jose Navío, Teresa González-Hombrado, Laura Salido, Marina Thuissard-Vasallo, Israel Jiménez-Díaz, Ana Llorente, Jesús Cebrián, Laura Lojo, Leticia Steiner, Martina Cobo, Tatiana Martín, María Dolores García-Castro, Marta Castro, Patricia Muñoz-Fernández, Santiago Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
title | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
title_full | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
title_fullStr | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
title_full_unstemmed | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
title_short | Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases |
title_sort | impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997274/ https://www.ncbi.nlm.nih.gov/pubmed/33671007 http://dx.doi.org/10.3390/vaccines9030203 |
work_keys_str_mv | AT richipatricia impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT yustejose impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT navioteresa impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT gonzalezhombradolaura impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT salidomarina impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT thuissardvasalloisrael impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT jimenezdiazana impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT llorentejesus impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT cebrianlaura impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT lojoleticia impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT steinermartina impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT cobotatiana impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT martinmariadolores impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT garciacastromarta impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT castropatricia impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases AT munozfernandezsantiago impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases |